Skip to contentI
Insight Molecular Diagnostics Inc.
I
IMDXInsight Molecular Diagnostics Inc. Q2 2024 · 10-Q
Revenue$104.00K$104.00K−77.5% vs Q2 2023 Net Income-$4.53M-$4.53MN/M vs Q2 2023 EPS Diluted-$0.36-$0.36N/M vs Q2 2023 Gross Profit$50,000−81.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Insight Molecular Diagnostics Inc. · CIK 1642380 · Engraved from SEC EDGAR
Operating Cash Flowderived-$5,978,000N/M Free Cash Flowderived-$6,169,000— Margins · derivedGross margin48.1%−10.7 pt vs Q2 2023
Operating margin-4453.8%−2662.5 pt vs Q2 2023
Net margin-4355.8%−2556.0 pt vs Q2 2023
ended Jun 30, 2024 · filed Aug 8, 2024 · 39 d after period end